Natalie Jachym
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Natalie Jachym has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Abby E. Odle
Department of Microbiology and Immunology, University of Iowa, Iowa City, IA 52242, USA
1 shared publication - Abhishek Kumar Verma
Department of Microbiology and Immunology, University of Iowa, Iowa City, IA 52242, USA
1 shared publication - Fang Li
Department of Pharmacology, University of Minnesota Medical School, Minneapolis, USA
1 shared publication - Gang Wang
Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA
1 shared publication Jack Deno
Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, USA
1 shared publication- Jian Zheng
Department of Microbiology and Immunology, School of Medicine, University of Louisville, Louisville, KY 40202, USA
1 shared publication
Latest Publications
- Open Access
- 23 January 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (5)
A T cell–based SARS-CoV-2 spike protein vaccine provides protection without antibodies
SARS-CoV-2 spike–based vaccines are used to control the COVID-19 pandemic. However, emerging variants have become resistant to antibody neutralization and further mutations may lead to full resistance. We tested whether T cells alone could provide protection without antibodies. We designed a T cell–based vaccine in which SARS-CoV-2 spike sequences were rearranged and attached to ubiquitin. Immunization of mice with the vaccine induced no specific antibodies, but strong specific T cell responses. We challenged mice with SARS-CoV-2 wild-type strain or an Omicron variant after the immunization and monitored survival or viral titers in the lungs. The mice were significantly protected against death and weight loss caused by the SARS-CoV-2 wild-type strain, and the viral titers in the lungs of mice challenged with the SARS-CoV-2 wild-type strain or the Omicron variant were significantly reduced. Importantly, depletion of CD4 + or CD8 + T cells led to significant loss of the protection. Our analyses of spike protein sequences of the variants indicated that fewer than one-third presented by dominant HLA alleles were mutated and that most of the mutated epitopes were in the subunit 1 region. As the subunit 2 region is conservative, the vaccines targeting spike protein are expected to protect against future variants due to the T cell responses.
- 23 January 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (5)
Open AccessA T cell–based SARS-CoV-2 spike protein vaccine provides protection without antibodies
SARS-CoV-2 spike–based vaccines are used to control the COVID-19 pandemic. However, emerging variants have become resistant to antibody neutralization and further mutations may lead to full resistance. We tested whether T cells alone could provide protection without antibodies. We designed a T cell–based vaccine in which SARS-CoV-2 spike sequences were rearranged and attached to ubiquitin. Immunization of mice with the vaccine induced no specific antibodies, but strong specific T cell responses. We challenged mice with SARS-CoV-2 wild-type strain or an Omicron variant after the immunization and monitored survival or viral titers in the lungs. The mice were significantly protected against death and weight loss caused by the SARS-CoV-2 wild-type strain, and the viral titers in the lungs of mice challenged with the SARS-CoV-2 wild-type strain or the Omicron variant were significantly reduced. Importantly, depletion of CD4 + or CD8 + T cells led to significant loss of the protection. Our analyses of spike protein sequences of the variants indicated that fewer than one-third presented by dominant HLA alleles were mutated and that most of the mutated epitopes were in the subunit 1 region. As the subunit 2 region is conservative, the vaccines targeting spike protein are expected to protect against future variants due to the T cell responses.